NewsBizkoot.com

Author: admin

  • Economist Bibek Debroy’s other side: Scholarly works and many awards

    World Bank lowers 2023 growth forecast from 3% to 1.9%, says dangerously close to recession







    Recently, India’s leading economist and Chairman of the Economic Advisory Council to the Prime Minister (EAC-PM) Bibek Debroy has been conferred a Lifetime Achievement Award recently by the Australia-India Chamber of Commerce (AICC), a business network that seeks to facilitate, nurture and transform Australia-India business.

    This highly coveted honour was bestowed upon Debroy in appreciation of his outstanding contribution and service towards growing economic prosperity in India. But there’s another side of the economist in Debroy.

    Bibek DebroyHandout

    An astute scholar, he has translated the unabridged version of the Mahabharata into English. He has also translated the Bhagavad Gita, the Harivamsa, the Vedas and Valmiki’s Ramayana (in three volumes). He has translated the Bhagavata Purana (in three volumes), the Markandeya Purana (one volume), the Brahma Purana (two volumes) and the Vishnu Purana (one volume).

    He is only the second person to have translated both the Mahabharata and the Ramayana, in unabridged form, into English. Sharing this information after his meeting with Debroy on Wednesday, filmmaker-actor Rahul Mittra said he was presented the unabridged version of the Mahabharata into English by Debroy, in a series of 10 volumes.

    Rahul Mittra shared photos on his Instagram handle @ramitts and wrote: “Enlightened to meet up with top economist Padma Shri Dr Bibek debroy, Chairman of the Economic Advisory Council to Prime Minister of India (EAC-PM) and acclaimed Sanskrit scholar along with his gracious wife Suparna at their lovely home and to be presented with his 10 volume unabridged translation of the Mahabharata !!”

    Debroy’s work on poverty alleviation

    Educated in Calcutta, Delhi and Cambridge, Bibek Debroy has worked in the realm of academia, the government and research institutions. When Niti Aayog (the successor to the former Planning Commission) was set up in January 2015, Bibek Debroy was a Member of the Aayog from January 2015 till August 2017 after which he became the Chairman of the Economic Advisory Council to the Prime Minister.

    Bibek Debroy has worked on poverty, inequality, development, governance, law reform and international trade issues and has been the Chairman of a Committee set up by the Chief Minister of Jharkhand (2010-12) to recommend a development plan for the State and a Member of the Rajasthan Chief Minister’s Economic Advisory Council (2014-15).

    Bibek Debroy

    Bibek Debroy with Rahul MittraInstagram

    He was also Chairman of a High-Powered Committee for Restructuring the Railways, set up by Union government (2014-2015). From September 2018 to September 2022, he was the President of the Indian Statistical Institute. He has received Lifetime Achievement Award by US-India Business Summit (2016) and Skoch Foundation award (2022) and Padma Shri in 2015.

  • Indian stock market soars to record high despite global headwinds

    Sensex crosses 50,000-mark on Thursday; Markets upbeat after Biden swearing-in







    The Indian stock market on Thursday touched a new high amid the looming risk of a global economic downturn, the ongoing Russia-Ukraine war and uncertainty around unusually large-scale unrest in China.

    The benchmark BSE Sensex recorded a fresh high of 63,583 points and Nifty-fifty of NSE also rose to a record-breaking high of 18,874 points. According to Reuters poll, the market is expected to remain bullish throughout the next year and grow by 9% by the end of 2023.

    The growth momentum in the domestic indices can be attributed partly to the softening inflation expectations and less hawkish stance on monetary policy by the Federal Reserve and Reserve Bank of India (RBI).

    SensexIANS

    Experts believe that RBI will likely slow the rate hikes in the upcoming Monetary Policy Committee (MPC) meet, which will begin on December 5th. The analysts predict that the rate hike could be between 25-35 basis point, which is down from the previous hike of 50 basis point in September. The likely move to taper further rate hike by RBI is in line with the Fed’s stance of smaller incremental hike.

    In a recent speech at the Brookings institution, Federal Reserve chair Jerome Powell said, “Monetary policy affects the economy and inflation with uncertain lags, and the full effects of our rapid tightening so far are yet to be felt. Thus, it makes sense to moderate the pace of our rate increases as we approach the level of restraint that will be sufficient to bring inflation down.”

    Other than the less aggressive future rate hikes, global cues like softening commodity prices (especially plunging crude prices) and the strong net inflow of Foreign Institutional investors (FIIs) in the Indian equity market is driving up the market optimism.

    sensex

    Apart from that, the strengthening of domestic demand, which can be observed through the acceleration in credit growth and increased risk appetite of investors in the equity market also contributes to the surge in the domestic indices.

    “The prospects for Indian markets remain bright over medium term as structural growth drivers for Indian economy are intact and India’s macroeconomic parameters remain resilient against challenges in the global economy,” said Hemant Kanawala, Executive Vice President and Head of Equity at Kotak Mahindra Life Insurance.

    However, the future trajectory of the market sentiment will likely be influenced by RBI‘s upcoming Monetary Policy Committee (MPC) meeting on December 5th, the US Federal Open Market Committee (FOMC) meeting on December 14th and the concerns over the economic consequences of widespread protests in China on global supply chain.

  • Cipla launches leuprolide acetate injection depot 22.5 mg in US


    Cipla Limited and its wholly owned subsidiary Cipla USA Inc., has announced the launch of leuprolide acetate injection depot 22.5mg.
     
    The product was approved by the United States Food and Drug Administration (FDA) based on a New Drug Application (NDA) submitted under the 505(b)(2) regulatory pathway.
     
    Leuprolide acetate injection depot contains 22.5 mg of leuprolide acetate for 3-month administration given as a single dose injection. It is supplied as lyophilized microspheres in a single dose vial as a kit with a prefilled syringe containing 2ml 0.8% mannitol solution and an easy-to-use Mixject transfer device for a single dose injection. It is indicated for palliative treatment of advanced prostate cancer.
     
    Arunesh Verma, CEO – Cipla North America, said, “The launch of leuprolide acetate injection depot reinforces our commitment as an organization to bring high quality and affordable treatments to patients in the US. Enabling access to high-quality treatments is core to our purpose of “Caring for Life”. This launch aligns with our strategy for growth in the complex product segment.”
     
    The active ingredient, route of administration, dosage form and strength are the same as Lupron depot 22.5 mg strength, from Abbvie.
     
    According to IQVIA, Lupron depot 22.5mg had US sales of approximately USD 197 million for the 12-month period ending September 2022.

  • US FDA grants fast track designation to Kintara Therapeutics’ REM-001 to treat cutaneous metastatic breast cancer


    Kintara Therapeutics, Inc., a biopharmaceutical company focused on the development of new solid tumour cancer therapies, announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kintara’s REM-001 Therapy for the treatment of patients with cutaneous metastatic breast cancer (CMBC).

    REM-001 was studied in four phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to-date of 80% complete responses of CMBC evaluable lesions, and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is focused on securing the funding necessary to restart a 15-patient study in CMBC patients in advance of a phase 3 study.

    “The receipt of Fast Track Designation represents an important regulatory milestone for our REM-001 Therapy program,” said Robert E. Hoffman, president and CEO of Kintara. “We believe this designation is a key component of our future clinical and regulatory strategy as we continue to seek funding, in particular grants, to restart REM-001 clinical development as soon as possible.”

    Dennis Brown, Ph.D., chief scientific officer of Kintara added, “This designation from the FDA emphasizes the important unmet medical need for safe and effective therapeutic options to address CMBC. We have extensive data in hand to support the advancement of this clinical program and look forward to the continued investigation of our drug candidate in the next study as planned.”

    Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Some of the significant benefits of FTD include:

    Enhanced access to the FDA including opportunities for more frequent meetings and written consultation throughout the remaining development of REM-001.

    Drugs with FTD are eligible to apply for Accelerated Approval and Priority Review at the time of a New Drug Application (NDA) submission, which may result in faster product approval.

    FTD also allows for ‘rolling review’ where Kintara may submit completed sections of the REM-001 NDA as they become available rather than at the end of development.

    Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programmes.

  • Akums Drugs enters into a joint association with Leiutis and Biophore for first-of-its-kind therapeutics


    Contract drug manufacturing organisation (CDMO) major Akums Drugs and Pharmaceuticals Ltd has announced partnership with Leiutis Pharmaceuticals LLP and Biophore India Pharmaceuticals for research and development of a range of products for multiple therapies, in order to leverage the research expertise and combined manufacturing capacities to introduce first-of-its-kind products in India
     
    The company expects that this association is set to bring succour in therapy areas of CNS disorders, Pain management, and Hormonal disorders, where there is a gap in meeting the needs of patients in an effective, safe, and convenient manner. It also leverages the strengths of each of the companies resulting in an innovation strategy creating a unique value proposition to doctors and patients in India.
     
    This tripartite association will see Akums manufacture & commercialise the products created by Leiutis Pharmaceuticals LLP and API from Biophore.  These unique products will be launched and marketed in India and the rest of the world with potential to bring about useful therapies and bridge the gaps in the treatment of ailments and diseases across the world.
     
    The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas, within the next five years, both in India and other global markets and with the first few products expected to be commercialised in the next two years. The agreement was signed at the CPhI event and exhibition on November 30, 2022 at Greater Noida in the presence of Prof(Dr). Y.K Gupta, president AIIMS Bhopal & president AIIMS Jammu & Former Dean & HoD Pharmacology, AIIMS Delhi.
     
    “A significantly large number of patients suffer from these diseases in India and globally, requiring treatment for several years and often having suboptimal experience with the available treatment options. In association with Leiutis and Biophore, we are committing to bringing unique products made available to the physicians and patients for improved clinical outcomes”, said Sanjeev Jain, founder, promoter and director, Akums.  
     
    Dr. Jagadeesh Babu Rangisetty, Founder and CEO of Biophore said, “It’s such an exciting prospect to partner with two other amazing organisations in the global pharma space. The aim is to combine our key competencies, capacities, and our passion for providing new therapies globally proven through clinical outcomes and to improve the lives of patients”.
     
    “Innovative therapies should address two objectives; ameliorate suffering and improve quality of life. Innovation is a collaborative journey & I am very excited to be part of this journey. It gives me immense pride to mention that the products, technology, APIs, and manufacturing are developed and made in India,” said K Chandrasekhar, CEO of Leiutis Pharmaceuticals LLP.
     
    Akums Drugs, claimed as India’s largest Contract Research and Manufacturing (CRAMS) organisation, currently manufactures around 12% of the country’s total medicinal requirements. The organisation deals in the manufacturing and export of formulations in a wide spectrum of dosage forms & therapeutic segments.
     
    Akums with reach to different markets, operates 15 fully-certified, state-of-the-art manufacturing facilities across the country. This is coupled with the company’s expertise in manufacturing and commercializing virtually all types of formulations, such as tablets, capsules, oral liquids, injections, creams, ointments, etc.
     
    Leiutis Pharmaceuticals LLP, a pharmaceutical product innovation company that creates innovative products that advance treatment in specific therapeutic areas has expertise in nanotherapeutics, and innovation which supports the next generation of speciality medicines. It has proprietary drug delivery technology, especially for the advancement of treatment in pain management, CNS disorders, cancer, immunomodulators, CVS disorders, hormonal disorders, and supportive care.
     
    Biophore Pharmaceuticals Pvt Ltd, an established pharmaceutical company that develops and manufactures niche pharmaceutical products for the generic industry, has state-of-the-art, multipurpose Active Ingredient manufacturing facilities in India comply with cGMP standards and meet the requirements of US and EU Drug regulatory authorities. Its technology development centre in Hyderabad is equipped with infrastructure that facilitates the entire process of drug research from conceptualisation to regulatory submissions. The company has filed over 100 drug master files and 150 patents for its unique portfolio. Biophore is one of the world’s leading API companies, ranking in the top 10 US DMF filers with the US FDA in the last five years.

  • Bharat Biotech’s intranasal Covid vaccine receives CDSCO approval


    Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and developer of vaccines for infectious diseases, has announced that its needle-free intranasal Covid vaccine iNCOVACC (BBV154) has received approval from the Central Drugs Standard Control Organisation (CDSCO) under restricted use in emergency situation for ages 18 and above, in India, for heterologous booster doses.
     
    iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilized SARS-CoV-2 spike protein. This vaccine candidate was evaluated in phases I, II and III clinical trials with successful results. iNCOVACC has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries.
     
    iNCOVACC was developed in partnership with Washington University, St. Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated in preclinical studies for efficacy. Product development related to preclinical safety evaluation, large-scale manufacturing scale up, formulation and delivery device development, including human clinical trials were conducted by Bharat Biotech. Product development and clinical trials were funded in part by the Government of India, through the Department of Biotechnology’s, Covid Suraksha Programme.
     
    Dr. Krishna Ella, chairman & managing director, Bharat Biotech, said, “iNCOVACC is an intranasal vaccine for the primary 2-dose schedule, and heterologous booster dose. This is a great achievement for us and the global scientific community to enable nasal administration of Covid vaccines. Despite the lack of demand for Covid vaccines, we continued product development in intranasal vaccines to ensure that we are well-prepared with platform technologies for future infectious diseases. We thank the Ministry of Health, CDSCO, Department of Biotechnology, Technology Development Board, and Washington University, St. Louis, for their support and guidance. iNCOVACC has been designed for efficient distribution, easy and pain-free administration. We have also initiated development of variant-specific vaccines for Covid for future preparedness.”
     
    Clinical trials were conducted to evaluate iNCOVACC as a primary dose schedule, and as heterologous booster dose for subjects who have previously received two doses of the two commonly administered Covid vaccines in India. Immunogenicity was evaluated through serum neutralizing antibodies by PRNT assays and serum IgG’s through ELISA’s. To evaluate vaccine, taken through the intranasal route, IgA’s were evaluated by ELISA in serum and saliva. Evaluation was also carried out for ability iNCOVACC to elicit long-term memory T and B cell responses against the ancestral and omicron variants.
     
    Dr. Rajesh S. Gokhale, secretary, DBT, and Chairperson, BIRAC, lauded the efforts of the scientific community and said, “DBT is fostering biotech enterprises & innovation ecosystem and strategically strengthening Indian bioeconomy. DBT, along with BIRAC, is dedicated to the development of effective and safe Covid-19 vaccines under Mission Covid Suraksha. The DCGI’s approval of Bharat Biotech’s intranasal vaccine iNCOVACC (BBV154) to be used as a heterologous booster dose against currently available Covid-19 vaccines is a moment of great pride for our country. This move will further strengthen our collective fight against the pandemic and broaden vaccine coverage.”
     
    “We are excited by the expansion of the EUA for iNCOVACC as a booster, which enables this intranasal vaccine to be used by many more people, and hopefully curtail transmission,” said Michael S Diamond, MD, PhD of Washington University in St. Louis, who co-developed the nasal vaccine technology with Washington University colleague David Curiel, MD, PhD. “This approval will increase the options for people to get vaccinated and protected against the SARS-CoV-2 virus during the ongoing pandemic.”
     
    Washington University licensed the vaccine technology to Bharat Biotech in 2020 for further development. iNCOVACC was evaluated to determine its impact on safety. The reactogenic events and adverse events that were documented during the trial were highly comparable to published data from other Covid-19 vaccines. Product development data will be submitted to peer reviewed journals and will be made available in the public domain.
     
    iNCOVACC has the double benefit of enabling faster development of variant-specific vaccines and easy nasal delivery that enables mass immunization to protect from emerging variants of concern. It promises to become an important tool in mass vaccinations during pandemics and endemics. With the receipt of this approval, launch dates, pricing and availability will be announced in due course of time.
     
    iNCOVACC is stable at 2-8°C   for easy storage and distribution. Bharat Biotech has established large manufacturing capabilities at multiple sites across India, including Gujarat, Karnataka, Maharashtra and Telangana, with operations pan India.

  • P&G Health’s “Na Na Anaemia Bus Yatra” to travel across 20 cities to raise awareness around iron deficiency anaemia

    [ad_1]


    Commemorating Iron Deficiency Day 2022 (IDD), P&G Health in association with Federation of Obstetric and Gynaecological Societies of India (FOGSI) has stepped up on efforts to raise awareness about Iron Deficiency Anaemia (IDA) with the “Na Na Anemia Bus Yatra”.
     
    Flagged off from Rishikesh by Milind Thatte, Managing Director, Procter & Gamble Health Limited and Dr Hrishikesh Pai, President, FOGSI, the “Na Na Anaemia Bus Yatra” will travel to 20 cities across the 5 states of Uttarakhand, Uttar Pradesh, Bihar, Jharkhand and West Bengal over 40 days, culminating in Kolkata on January 4, 2023.
     
    Milind Thatte, managing director, Procter & Gamble Health Limited, said, “P&G Health has been dedicated to awareness and education efforts on iron deficiency through our flagship brand Livogen, for over 50 years in India. Through the “Na Na Anaemia Bus Yatra” in collaboration with FOGSI, we aim to create awareness till the last mile and empower people to identify early symptoms of IDA and take measures to overcome them. Under this initiative, free screening will be provided to over 5000 individuals along with Blood Pressure monitoring and an examination by a gynaecologist/physician.”
     
    Iron deficiency affects all ages, with children, women who are pregnant or menstruating, and people on kidney dialysis among those at the highest risk for this condition. The World Health Organization (WHO) estimates that iron deficiency contributes to 50 per cent of all cases of anaemia. The National Family Health Survey (NFHS-5) data revealed that 1 in every 2 women in India is anaemic and the prevalence is around 57 per cent in non-pregnant women & 52 per cent in pregnant women. One in three women suffer from iron deficiency symptoms including tiredness, dizziness, paleness and hair fall3. But these symptoms are often ignored, making early identification of these symptoms and seeking timely diagnosis the need of the hour.
     
    Dr Hrishikesh Pai, president, FOGSI added, “We are pleased to join hands with P&G Health for this promising campaign which contributes towards creating awareness around iron deficiency anaemia and its associated problems. India is endemic for nutritional deficiencies and has one of the highest reported cases of iron deficiency and anaemia cases. However, iron deficiency can often be confused with deficiency of vital vitamins prevalent in our country, and at times overlooked. We hope that the Bus Yatra is instrumental in creating on-ground awareness and reaching the grassroot levels.”
     
    As an ongoing effort, P&G Health is constantly engaging with patients, consumers and Healthcare Professionals (HCPs) to help educate and raise awareness on iron deficiency anaemia. A recently published Expert Consensus Publication, co-authored by P&G Health with renowned experts, brought into focus the impact of iron deficiency on the health of peri-menopausal women in India. P&G Health is also contributing to scientific learning and knowledge exchange forums for medical practitioners, including diagnostic workshops, continuing medical education, case-based discussions and global discussion forums.

    [ad_2]

    Source link

  • Henlius begins patient dosing in head-to-head trial of Hansizhuang to treat ES-SCLC

    [ad_1]


    Shanghai Henlius Biotech, Inc., a global biopharmaceutical company, announced that the first patient was dosed in NCT05468489, a bridging head-to-head trial in the United States comparing Hansizhuang (serplulimab), an innovative anti-PD-1 monoclonal antibody (mAb) independently developed by the company to standard of care Atezolizumab (anti-PD-L1 mAb). Based on the positive feedback of FDA Biologics license Application (BLA) submission for Hansizhuang for the treatment of extensive-stage small cell lung cancer (ES-SCLC) and the discussion results of the FDA’s Class C consultation meeting, Henlius plans to recruit 100 pairs of US patients with ES-SCLC to evaluate the efficacy of Hansizhuang.

    In April 2022, the company announced that US Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for Hansizhuang for the treatment of small cell lung cancer (SCLC). The ODD granted by the FDA is beneficial for the continuous development of Hansizhuang and the enjoyment of certain policy support in terms of registration and commercialization in the United States. In China, the New Drug Application (NDA) of Hansizhuang in combination with chemotherapy for the first-line treatment of ES-SCLC has been accepted by the National Medical Products Administration (NMPA). At present, there is no anti-PD-1 mAb approved for the first-line treatment of SCLC worldwide. Hansizhuang is expected to become the world’s first anti-PD-1 mAb for the first-line treatment of SCLC and to fill the clinical gap in the next five years.

    SCLC is the most aggressive subtype of lung cancer, accounting for 15% to 20% of all lung cancer cases. SCLC exhibit high malignancy, strong invasiveness, early metastasis, fast disease progression, and a poor prognosis. At present, anti-PD-L1 mAbs combined with chemotherapy have been recommended by clinical practice guidelines abroad as the first-line treatment for ES-SCLC, but there is no anti-PD-1 mAb approved worldwide, suggesting the need for more effective treatments in this patient population.

    Henlius has conducted an international multi-centre phase 3 study of Hansizhuang plus chemotherapy as first-line treatment for patients with ES-SCLC. The study has set up a total of 128 sites in various countries including China, Turkey, Poland, and Georgia, and enrolled 585 subjects who were screened from 114 sites, among whom 31.5% were White. The results of ASTRUM-005 were presented for the first time in an oral report at the 2022 ASCO annual meeting, and ASTRUM-005 went on to become the first immunotherapy clinical study of SCLC to be published in The Journal of the American Medical Association (JAMA, impact factor of 157.3), one of the top four medical journals in the world. As of data cut-off for the interim analysis (October 22, 2021), median overall survival (OS) was significantly longer in the serplulimab group (15.4 months) than in the placebo group (10.9 months), forming a new world record. In addition, the study showed good safety and consistent efficacy over time.

    Hansizhuang is the first innovative mAb developed by Henlius. Up to date, 2 indications are approved for marketing in China, 2 NDAs have been accepted by the NMPA. Since launched in March 2022, Hansizhuang has been approved by the NMPA for the treatment of MSI-H solid tumours and squamous non-small cell lung cancer, benefiting more than 9,700 Chinese patients. Its synergy with in-house products of the company and innovative therapies are forging ahead. It has successively obtained clinical trial licenses in China, the United States, the European Union and other countries and regions to initiate 11 clinical trials on immuno-oncology combination therapies in a wide variety of indications, such as lung cancer, esophageal carcinoma, head and neck squamous cell carcinoma and gastric cancer, etc., and covering the full range of first-line treatments of lung cancers. As of now, Hansizhuang has enrolled more than 3,100 subjects around the world, and the proportion of White is over 30% in two MRCTs including ASTRUM-005. Such a large amount of global clinical data is also expected to bolster the marketing approval of Hansizhuang in overseas markets such as the European Union and to lay a foundation for global clinical application. The bridging trial carried out in the United States will also further promote the global development of Hansizhuang.

    In the future, the company will continue to emphasize unmet clinical needs, actively promote the progress of this bridging study and the combination immunotherapy of serplulimab, offering high-quality, affordable, and innovative medicines to patients worldwide.

    This randomised, open-label clinical study aims to compare the efficacy and safety of serplulimab with atezolizumab (anti-PD-L1 mAb) when combined with chemotherapy (carboplatin-etoposide) in previously untreated US patients with extensive-stage small cell lung cancer (ES-SCLC). Eligible patients will be randomised 1:1 to receive intravenous infusion of either serplulimab (300 mg) or atezolizumab (1200 mg) in combination with chemotherapy every 3 weeks. The primary objective of this study is to compare the efficacy of the two treatment regimens in previously untreated US ES-SCLC patients. Secondary objectives are to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of serplulimab in combination with chemotherapy. The primary endpoint is overall survival (OS). Secondary endpoints include progression-free survival (PFS), PFS2, objective response rate (ORR), duration of response (DOR), safety, pharmacokinetic characteristics, and immunogenicity.

    Henlius is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases.

    [ad_2]

    Source link

  • Circuit Clinical inks partnership with Middletown Medical to expand access to clinical research for 100K+ patients in Hudson Valley

    [ad_1]


    Circuit Clinical, one of the fastest growing integrated research organizations, has expanded their presence in the Hudson Valley region through a partnership with Middletown Medical, a top-tier, multi-specialty physician group, increasing access to clinical research as a care option to an additional 100,000 patients that Middletown Medical serves. This partnership will bring trials to a more diverse patient population—comprised of approximately 50% non-white individuals.

    The breadth of Middletown Medical’s primary and specialty care, combined with Circuit’s commitment to improving patient access and inclusion in clinical trials, will bring new care opportunities to Middletown’s patients through the provider relationships they already trust – further positioning the region as a destination for medical research and advancements. This partnership will initially include 11 Principal Investigators, participating in specialties such as, but not limited to, cardiology, rheumatology, neurology, gastroenterology, and family medicine.

    “Patient care is a top priority for Middletown Medical and we are committed to providing any and all opportunities to our physicians and the communities they serve,” said Dr. Rajan Gulati, president of Middletown Medical.

    Middletown Medical and Circuit Clinical are committed to reducing the burden on patients who opt in for research participation. Along with localizing patient care within the Middletown Medical physicians’ offices, Circuit’s approach to transforming the patient journey includes hybrid care options through telemedicine, fully decentralized trial solutions, as well as trialjourney.com—an award-winning patient experience platform for finding trials and leaving site ratings and reviews to improve the experience of participating in clinical trials. This variety of care options can help eliminate traditional care obstacles that have created a burden for patients to participate in clinical research. Furthermore, patient participation in research will serve to benefit both individuals and communities, including offering extra care visits without co-pays, strengthening the patient-provider relationship, and often leading to improved health outcomes through a better and more personal care experience.

    This collaboration was made possible through strategic partnerships with Labcorp—a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions—as well as Medidata—a Dassault Systems company that is powering smarter treatments and healthier people with the world’s most trusted platform for clinical development, commercial, and real-world data.

    “We are beyond excited to expand our national research network through amazing partnerships like this one with Middletown Medical,” said Irfan Khan, MD, CEO of Circuit Clinical. “Together we can empower patients to engage with clinical trials as a care option. The combined efforts of Circuit Clinical and our strategic partners, Labcorp and Medidata, allow us to make partnerships like this with Middletown Medical not only a reality, but as optimal and innovative as possible.”

    Middletown Medical is a multi-specialty physicians’ group dedicated to providing patients with top quality, comprehensive care in a warm and caring environment which delivers care to over 100,000 patients throughout Orange, Sullivan, and Ulster counties in New York state.

    Circuit Clinical, one of the fastest-growing integrated research organizations in the USA, is dedicated to empowering patients to choose clinical research as a care option.

    [ad_2]

    Source link

  • Warner Bros, Discovery, Amazon Studios partner to produce animated DC projects

    Mickey Mouse Turns 90 – Five Facts You Didnt Know







    Warner Bros. Discovery’s television-focused production arm and Amazon Studios have collaborated to produce new animated projects based on DC Comics’ IP (intellectual property).

    During a keynote presentation earlier this week, Warner Bros. Television Studios’ chairwoman Channing Dungey discussed some of the major changes the company plans to undertake as a part of CEO David Zaslav’s vision for its future, reports The Verge.

    According to Dungey, Zaslav has shown a much greater interest in collaborating with others and distributing the studio’s content on platforms that it does not own outright.

    Warner Bros, Discovery, Amazon partner to produce animated DC projects

    Warner Bros. Discovery, Amazon partner to produce animated DC projectsIANS

    “David Zaslav has been much more open to exploring all of our animated IP and being able to do it on different platforms,” Dungey was quoted as saying.

    “Certainly, HBO Max is going to be our first stop, but we’re already in the process of closing a big deal with Amazon that’s going to feature some of our DC-branded content in animation,” she added.

    Zaslav expressed interest in returning to the Harry Potter universe to capitalise on the series’ ongoing success. Dungey echoed this sentiment and claimed that the studio is currently having “a number of different conversations about.”

    DC Comics, Batman, Superman, Wonder Woman

    DC Comics, Batman, Superman, Wonder WomanDC Comics, Facebook

    “I wish I could tell you that something was imminent on the horizon but there is a lot of interest and a lot of passion for it, so absolutely,” Dungey replied to a question about if a scripted Harry Potter would be in the works.

    (WIth inputs from IANS)